Cardiorenal dysfunction is a major contributor to morbidity, rehospitalization, and mortality in advanced heart failure (HF) and cardiogenic shock. Traditional decongestive approaches—loop diuretics, combination natriuretics, and ultrafiltration—are frequently inadequate in the setting of diuretic resistance or persistent venous and interstitial congestion, underscoring a substantial therapeutic gap.
